Top 3 oncology drug approvals January: Yescarta^®, Ninlaro^® & Brukinsa^®

The advent of the new year has brought with it a plethora of new treatment options in the hematologic oncology arena as several drugs received new designations. Read our full roundup below to find out about expanses in therapeutic choices for multiple myeloma, leukemia and lymphoma subtypes. Ninlaro® (ixazomib) Approved: 18 January 2023 Approving body: NICE Indication: Relapsed or refractory multiple myeloma January saw the approval of an oral-triplet therapy in the UK for multiple myeloma patients. NICE recommended the use of ixazomib in combination with lenalidomide and dexamethasone, based on encouraging data from the TURMALINE-MM1 study. The study demonstrated...